Business Context and Reporting Period
This Form 8-K filing by Trevi Therapeutics, Inc. (TRVI) reports on events occurring on September 18, 2019. The registrant is a Delaware corporation with principal executive offices in New Haven, Connecticut, and its common stock trades on The Nasdaq Stock Market LLC. The company is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
The primary material change reported is the adoption of the Executive Separation Benefits and Retention Plan by the Compensation Committee on September 18, 2019. This plan supersedes previous separation benefits in award agreements or employment letters for the CEO, CFO, and other officers ("Covered Executives").
- Standard Termination: Provides 12 months of base salary for the CEO and 6 months for other executives upon termination without cause or resignation for good reason (outside a Change in Control period).
- Change in Control (CIC) Termination: Provides 18 months of base salary for the CEO and 12 months for other executives if termination occurs within 12 months of a Change in Control.
- Additional CIC Benefits: Includes a lump sum target bonus (1.5x for CEO, 1.0x for others) and 100% acceleration of time-based equity vesting.
- Health Benefits: The company will pay COBRA premiums during the severance period unless the executive obtains similar coverage elsewhere.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or management commentary regarding business operations. The primary risk disclosed relates to the potential future cash outflows associated with the new separation benefits plan, contingent upon executive terminations or a Change in Control. The Board retains the discretion to amend or terminate the plan, subject to specific restrictions regarding adverse changes prior to a Change in Control.
Investor Verification Checklist
- Verify the specific terms of the attached Exhibit 10.1 (Executive Separation Benefits and Retention Plan) for complete legal definitions.
- Confirm the current employment status of the CEO and other Covered Executives to assess immediate liability.
- Review the company's cash position in recent 10-Q or 10-K filings to evaluate the ability to fund potential severance obligations.
- Monitor for any future filings regarding a Change in Control, which would trigger enhanced severance provisions.